Verbally administered Barthel Index as functional assessment in brain tumour patients

被引:33
作者
Brazil, L
Thomas, R
Laing, R
Hines, F
Guerrero, D
Ashley, S
Brada, M
机构
[1] ROYAL MARSDEN NHS TRUST, NEUROONCOL UNIT, SUTTON SM2 5PT, SURREY, ENGLAND
[2] INST CANC RES, SUTTON SM2 5PT, SURREY, ENGLAND
关键词
glioma therapy; neurological function; activities of daily living; Barthel Index;
D O I
10.1023/A:1005710729748
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To investigate verbally administered Barthel Index as a measure of functional status in patients with high grade gliomas. Background: Barthel Index (BI) is a performance score of activities of daily living which has been validated in patients with neurological disability. While any assessment of quality of life in brain tumour patients should include all the aspects of CNS function we concentrated on measurement of physical performance status and evaluated the role of BI as a measure of palliative effect of treatment in patients with high grade glioma undergoing radiotherapy. Methods: BI was verbally administered on 504 occasions in 107 patients with high grade glioma. The BI scores were correlated with Karnofsky performance score (KPS), and neurological performance score (NPS) as a measure of inter-index reliability The BI's prognostic value was assessed using actuarial survival data. Results: BI was sensitive to change and reflected the degree of functional impairment. In patients with high grade glioma BI correlated with KPS, and NPS (R-2 = 0.872 and 0.658 respectively). BI score was also of prognostic value in terms of survival. The median survival of patients with functional independence was 9 months with moderate disability 5 months and with severe disability 4 months. Conclusion: Verbally administered Barthel Index is easy to use, reliable and sensitive to change and is of prognostic value. It is a useful tool in the management of patients with gliomas, as an objective evaluation of palliative effectiveness of treatment in patients with functional disability.
引用
收藏
页码:187 / 192
页数:6
相关论文
共 19 条
[1]  
ALEXANDER JR, 1979, EPIDEMIOLOGY COMMUNI, V33, P91
[2]  
[Anonymous], EVALUATION CHEMOTHER
[3]   A MEDICAL-RESEARCH-COUNCIL TRIAL OF 2 RADIOTHERAPY DOSES IN THE TREATMENT OF GRADE-3 AND GRADE-4 ASTROCYTOMA [J].
BLEEHEN, NM ;
STENNING, SP .
BRITISH JOURNAL OF CANCER, 1991, 64 (04) :769-774
[4]   IMPROVING THE ACCEPTABILITY OF HIGH-DOSE RADIOTHERAPY BY REDUCING THE DURATION OF TREATMENT - ACCELERATED RADIOTHERAPY IN HIGH-GRADE GLIOMA [J].
BRADA, M ;
THOMAS, G ;
ELYAN, S ;
JAMES, N ;
HINES, F ;
ASHLEY, S ;
MARSH, H ;
BELL, BA ;
STENNING, S .
BRITISH JOURNAL OF CANCER, 1995, 71 (06) :1330-1334
[5]  
Collin C, 1988, Int Disabil Stud, V10, P61
[6]   A COMPARISON OF 5 STROKE SCALES WITH MEASURES OF DISABILITY, HANDICAP, AND QUALITY-OF-LIFE [J].
DEHAAN, R ;
HORN, J ;
LIMBURG, M ;
VANDERMEULEN, J ;
BOSSUYT, P .
STROKE, 1993, 24 (08) :1178-1181
[7]  
GANZ PA, 1988, CANCER, V61, P849, DOI 10.1002/1097-0142(19880215)61:4<849::AID-CNCR2820610435>3.0.CO
[8]  
2-B
[9]   RECORDING NEUROLOGICAL IMPAIRMENT IN CLINICAL-TRIALS OF GLIOMA [J].
GRANT, R ;
SLATTERY, J ;
GREGOR, A ;
WHITTLE, IR .
JOURNAL OF NEURO-ONCOLOGY, 1994, 19 (01) :37-49
[10]  
GRESHAM GE, 1980, ARCH PHYS MED REHAB, V61, P355